DESCRIPTION
Embosphere® Microspheres are biocompatible, hydrophilic, non-absorbable, precisely calibrated acrylic polymer microspheres impregnated with porcine gelatin and are available in a large range of sizes and concentrations.

HOW SUPPLIED
20-mL prefilled syringe with a standard Luer-lock tip, individually packaged in blister tray sealed by a Tyvek® peel-away lid. Plastic screw cap and plunger. Elastomer three-skirt plunger joint.

INDICATIONS
Embosphere Microspheres are designed to occlude blood vessels, for therapeutic or preoperative purposes, in the following procedures:
- Embolisation of hypervascular tumours and processes, including uterine fibroids, meningiomas, etc.
- Embolisation of the prostate arteries for relief of symptoms related to Benign Prostatic Hyperplasia.
- Embolisation of arteriovenous malformations.
- Haemostatic embolisation.

40-120 μm microspheres are more specifically designed for embolisation of meningiomas and liver tumours.

CONTRAINDICATIONS
- Patients unable to tolerate vascular occlusion procedures.
- Vascular anatomy precluding correct catheter placement.
- Feeding arteries too small to accept the selected microspheres.
- Presence or suspicion of vasospasm.
- Presence of distal arteries directly supplying cranial nerves.
- Presence of patent extra-to-intracranial anastomoses.
- High-flow arteriovenous shunts or with a diameter greater than the selected microspheres.
- Use in the pulmonary vasculature.
- Severe atherosclerosis.
- Patients with known allergy to gelatin.

50-100 μm, 40-120 μm and 100-300 μm microspheres are not recommended for use in the bronchial circulation.

POTENTIAL COMPLICATIONS
Vascular embolisation is a high-risk procedure. Complications may occur at any time during or after the procedure, and may include, but are not limited to, the following:
- Stroke or cerebral infarction
- Occlusion of vessels in healthy territories
- Vascular rupture and haemorrhage
- Neurological deficits
- Infection or haematoma at the injection site
- Allergic reaction, cutaneous irrigations
- Transient pain and fever
- Vasospasm
- Death
- Ischaemia at an undesirable location, including ischaemic stroke, ischaemic infarction (including myocardial infarction), and tissue necrosis
- Blindness, hearing loss, loss of smell, and/or paralysis
- Additional information is found in the Warnings section

CAUTION
DO NOT USE THIS PREFILLED SYRINGE TO DIRECTLY INJECT EMBOSPHERE MICROSPHERES. THIS IS A “RESERVOIR” SYRINGE. PLEASE REFER TO INSTRUCTIONS PARAGRAPH.

Embosphere Microspheres must only be used by specialist physicians trained in vascular embolisation procedures. The size and quantity of microspheres must be carefully selected according to the lesion to be treated, entirely under the physician’s responsibility. Only the physician can decide the most appropriate time to stop the injection of microspheres.

Do not use if blister tray, peel-away film, screw cap or syringe are damaged. This is a disposable product. Discard opened syringes after use. All procedures must be performed according to an aseptic technique.

For single patient use only - Contents supplied sterile
Do not reuse, reprocess, or resterilise. Reusing, reprocessing or resterilising may compromise the structural integrity of the device and lead to device failure, which in turn may result in patient injury, illness or death. Reusing, reprocessing or resterilising may also create a risk of contamination of the device and/or cause patient infection or cross infection including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient.

WARNINGS
- Embosphere Microspheres contain gelatin of porcine origin, and therefore, could cause an immune reaction in patients who are hypersensitive to collagen or gelatin. Careful consideration should be given prior to using this product in patients who are suspected to be allergic to injections containing gelatin stabilizers.
- Studies have shown that Embosphere Microspheres do not form aggregates, and, as a result, penetrate deeper into the vasculature as compared to similarly sized PVA particles. Care must be taken to choose larger sized Embosphere Microspheres when embolising arteriovenous malformations with large shunts to avoid passage of the spheres into the pulmonary or coronary circulation.
- Some of the Embosphere Microspheres may be slightly outside of the range, so the physician should be sure to carefully select the size of Embosphere Microspheres according to the size of the target vessels at the desired level of occlusion in the vasculature and after consideration of the arteriovenous angiographic appearance. Embosphere Microspheres size should be selected to prevent passage from artery to vein.
- Because of the significant complications of misembolisation, extreme caution should be used for any procedures involving the extracranial circulation encompassing the head and neck, and the physician should carefully weigh the potential benefits of using embolisation against the risks and potential complications of the procedure. These complications can include blindness, hearing loss, loss of smell, paralysis and death.
- Because of the tortuous vessels and duplicative feeding arteries in the pelvic area, extreme caution should be used when performing embolisation for the treatment of symptomatic Benign Prostatic Hyperplasia. Complications of misembolisation may include ischaemia of the rectum, bladder, scrotum, penis or other areas.
- Serious radiation induced skin injury may occur to the patient due to long periods of fluoroscopic exposure, large patient diameter, angled x-ray projections, and multiple image recording runs or radiographs. Refer to your facility’s clinical protocol to ensure the proper radiation dose is applied for each specific type of procedure performed. Physicians should monitor patients that may be at risk.
- Onset of radiation-induced injury to the patient may be delayed. Patients should be counseled on potential radiation side effects and whom they should contact if they show symptoms.
- Pay careful attention for signs of mistargeted embolisation. During injection carefully monitor patient vital signs to include SaO2 (e.g. hypoxia, CNS changes). Consider terminating the procedure, investigating for possible shunting, or increasing microsphere size if any signs of mistargeting occur or patient symptoms develop.
- Consider upsizing the microspheres if angiographic evidence of embolisation does not quickly appear evident during injection of the microspheres.

Warnings about use of small microspheres
- Careful consideration should be given whenever use is contemplated of embolic agents that are smaller in diameter than the resolution capability of your imaging equipment. The presence of arteriovenous anastomoses, branch vessels leading away from the target area or emergent vessels not evident prior to embolisation can lead to mistargeted embolisation and severe complications.
INSTRUCTIONS

• Position the catheter at the desired site and perform baseline angiography to evaluate the blood supply of the lesion.
• Embosphere Microspheres are available in a range of sizes. Because of the potential for misembolisation and the inherent variability in sphere sizes, the physician should be sure to carefully select the size of Embosphere Microspheres according to the size of the target vessels at the desired level of occlusion in the vasculature.
• Carefully select the size of microspheres according to the size of the vessels identified and the catheter used. Embosphere Microspheres are flexible particles that support temporary compression by 20 to 30% to facilitate passage through microcatheters. Studies have shown a direct correlation between the size of microspheres and the size of occluded vessels.
• Inspect packaging and syringe before use to ensure that they are intact. The external surface of the syringe is sterile.
• Unscrew the cap of the Embosphere Microsphere prefilled syringe and gently draw contrast agent directly into the reservoir syringe.
• The ideal suspension is usually obtained with a mixture of 50% contrast agent and 50% saline solution. To obtain a homogeneous suspension of Embosphere Microspheres, gently invert the 20-mL syringe several times. Contrast agent and 0.9% NaCl solution can be added in the same proportions to obtain a more diluted suspension.
• Do not use the 20-mL prefilled syringe to inject Embosphere Microspheres through the catheter!
• Remove all air from the syringe and connect it to one hub of the three-way stopcock.
• Draw up the suspension using a small syringe (1 to 3 cc) connected to another hub of the three-way stopcock. Avoid back and forth movements to reduce the risk of introducing air into the system. Check that the desired quantity and concentration of microspheres are used.
• Remove all air from the syringe.
• Screw the syringe onto the hub of the catheter, using the male Luer-lock connector of the stopcock.
• Open stopcock to connect the injection syringe with the catheter.
• Under continuous fluoroscopic control, slowly infuse microspheres into the blood stream. Always inject under free flow conditions. Reflux of microspheres can induce immediate ischaemia of healthy tissues or vessels.
• Continue infusion until the desired devascularisation is obtained. Studies have shown that Embosphere Microspheres penetrate more distally into the lesion than PVA particles of similar size. Reduction of the arterial blood supply to the lesion is therefore more progressive.
• At the end of the infusion, remove the catheter while maintaining gentle aspiration to avoid dislodging any residual microspheres still inside the catheter, then close the three-way stopcock.
• Remove the catheter.
• Discard any remaining Embosphere Microspheres and the used syringes.

CONSERVATION AND STORAGE
Embosphere Microspheres must be stored in a cool, dry, dark place in their original syringe and packaging. Use by the date indicated on the labels of the outer box and blister pack. Do not freeze.